SAR439859 clinical trials

A Phase 1 /2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of amcenestrant (SAR439859 ), administered orally as monotherapy, then in combination with other anti-cancer therapies in postmenopausal women with estrogen receptor-positive advanced breast cancer

This study looks at a new drug, amcenestrant, for postmenopausal women with advanced breast cancer. It tests its safety and how well it works, both alone and with other common cancer medicines.